Showing results (271-280 of 344) with videos related to
Sort By:
Pageof 35
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.Cancer Science|November 27, 2025
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple MyelomaToru Ebina, Masaki Ri, Yoshiaki Marumo, et al.Experimental Hematology & Oncology|April 21, 2016
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialTatsuo Ichinohe, Yoshiaki Kuroda, Shinichiro Okamoto, et al.European Journal of Haematology|November 6, 2013
Antitumor effects of bevacizumab in a microenvironment-dependent human adult T-cell leukemia/lymphoma mouse modelFumiko Mori, Takashi Ishida, Asahi Ito, et al.Journal of Experimental & Clinical Cancer Research : CR|March 24, 2021
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myelomaMitsuhito Hirano, Yoichi Imai, Yuta Kaito, et al.Hematological Oncology|November 26, 2022
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs studyKazutaka Sunami, Shin-Ichi Fuchida, Kenshi Suzuki, et al.Ejhaem|July 18, 2022
Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational studyTakafumi Nakayama, Yoshiko Oshima, Shigeru Kusumoto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2015
Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/LymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.British Journal of Haematology|November 22, 2011
CD48 as a novel molecular target for antibody therapy in multiple myelomaNaoki Hosen, Hiroyoshi Ichihara, Atsuko Mugitani, et al.Nature Communications|December 15, 2021
Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of MogamulizumabYuka Maeda, Hisashi Wada, Daisuke Sugiyama, et al.Pageof 35